Veracyte — Third Quarter 2026 Earnings Summary

Veracyte reported third-quarter 2026 total revenue of $151.8 million, a 15% increase from the prior year, driven by growth in its Afirma and Decipher Prostate testing franchises. The company achieved a GAAP net income of $31.5 million and generated $40.3 million in cash from operations, ending the quarter with $370.5 million in cash and short-term investments. Key business developments included the acquisition of Convergent Genomics, Medicare reimbursement for the Prosigna Breast test, and the milestone of serving over one million patients. Additionally, Veracyte announced a new $100 million share repurchase program and maintained its full-year 2026 revenue guidance between $590 million and $593 million.